94 related articles for article (PubMed ID: 5927938)
1. Is toxicity really necessary? II. Source and analysis of data.
Bross ID; Rimm AA; Slack NH; Ausman RK; Jones R
Cancer; 1966 Dec; 19(12):1785-95. PubMed ID: 5927938
[No Abstract] [Full Text] [Related]
2. Is toxicity really necessary? I. The question.
Bross ID; Rimm AA; Slack NH; Ausman RK; Jones R
Cancer; 1966 Dec; 19(12):1780-4. PubMed ID: 5927937
[No Abstract] [Full Text] [Related]
3. OBSERVATIONS ON THE USE OF CANCER CHEMOTHERAPEUTIC AGENTS IN PATIENTS WITH MYCOSIS FUNGOIDES.
WRIGHT JC; LYONS MM; WALKER DG; GOLOMB FM; GUMPORT SL; MEDREK TJ
Cancer; 1964 Aug; 17():1045-62. PubMed ID: 14202592
[No Abstract] [Full Text] [Related]
4. Nonhuman primates in evaluation of hematotoxicity.
Saslaw S; Carlisle HN
Ann N Y Acad Sci; 1969 Jul; 162(1):646-58. PubMed ID: 4979575
[No Abstract] [Full Text] [Related]
5. Microbial mutagenicity of chlorambucil, its half-mustard and mitomycin C: a modified screening strategy for genetic toxicology of bis-alkylating anti-tumour drugs.
Ferguson LR; Palmer BD; Denny WA
Anticancer Drug Des; 1988 Jun; 3(1):67-76. PubMed ID: 3132934
[TBL] [Abstract][Full Text] [Related]
6. Potentiating effects of caffeine on teratogenicity of alkylating agents in mice.
Fujii T; Nakatsuka T
Teratology; 1983 Aug; 28(1):29-33. PubMed ID: 6415842
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of dibromodulcitol (NSC-104800).
Andrews NC; Weiss AJ; Ansfield FJ; Rochlin DB; Mason JH
Cancer Chemother Rep; 1971 Feb; 55(1):61-5. PubMed ID: 5121653
[No Abstract] [Full Text] [Related]
8. The role of drug transport in resistance to nitrogen mustard and other alkylating agents in L518Y lymphoblsts.
Goldenberg GJ
Cancer Res; 1975 Jul; 35(7):1687-92. PubMed ID: 1055634
[TBL] [Abstract][Full Text] [Related]
9. Hematologic toxicity of mitomycin-C (MMC) administered every three weeks in combination schedules.
Jirillo A; Demicheli R
Haematologica; 1985; 70(1):80-1. PubMed ID: 3924764
[No Abstract] [Full Text] [Related]
10. Effects of antitumor agents and hyperbaric oxygen in normal and tumor-bearing rodents.
Nathanson L; Brown B; Maddock C; Hall TC
Cancer; 1966 Jul; 19(7):1019-25. PubMed ID: 4161090
[No Abstract] [Full Text] [Related]
11. Hematological toxicity of adjuvant portal liver infusion with fluorouracil, mitomycin and heparin.
Weber W; Metzger U; Laffer U; Egeli R
Anticancer Res; 1991; 11(1):365-8. PubMed ID: 1902076
[TBL] [Abstract][Full Text] [Related]
12. [Changes in the hematopoietic system during treatment with 5-fluorouracil].
Voznyĭ EK
Vopr Onkol; 1970 Apr; 16(4):64-7. PubMed ID: 5454548
[No Abstract] [Full Text] [Related]
13. Phase II study of hexamethylmelamine (NSC 13875).
Wilson WL; Schroeder JM; Bisel HF; Mrazek R; Hummel RP
Cancer; 1969 Jan; 23(1):132-6. PubMed ID: 5812585
[No Abstract] [Full Text] [Related]
14. Phase II trial of combination chemotherapy of colonic cancer with 5-fluorouracil, mitomycin C, and hexamethylmelamine.
Bruckner HW; Storch JA; Brown JC; Goldberg J; Chamberlin K
Oncology; 1983; 40(3):161-4. PubMed ID: 6405337
[TBL] [Abstract][Full Text] [Related]
15. CANCER CHEMOTHERAPY.
EISMAN SG; RICHARDSON FM
Med Sci; 1964 Mar; 15():63-72. PubMed ID: 14143132
[No Abstract] [Full Text] [Related]
16. COMBINED USE OF AB-132 (METUREDEPA, TURLOC) AND X-IRRADIATION IN THE MANAGEMENT OF ADVANCED BRONCHOGENIC CARCINOMA.
VELASCO HA; ROSS CA; WEBSTER JH; SOKAL JE; STUTZMAN L; AMBRUS JL
Cancer; 1964 Jul; 17():841-9. PubMed ID: 14184043
[No Abstract] [Full Text] [Related]
17. Drug resistance in cancer.
Curt GA; Clendeninn NJ; Chabner BA
Cancer Treat Rep; 1984 Jan; 68(1):87-99. PubMed ID: 6198082
[No Abstract] [Full Text] [Related]
18. Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
Nichols M; Bergevin PR; Vyas AC; Hamilin R
Cancer Treat Rep; 1976 Mar; 60(3):293-4. PubMed ID: 1260786
[No Abstract] [Full Text] [Related]
19. Methotrexate and the platelet count.
Ogston D; Dawson AA; Philip JF
Br J Cancer; 1968 Jun; 22(2):244-9. PubMed ID: 5660130
[No Abstract] [Full Text] [Related]
20. The efficacy of animal studies in predicting clinical toxicity of cancer chemotherapeutic drugs.
Schein P; Anderson T
Int J Clin Pharmacol; 1973 Nov; 8(3):228-38. PubMed ID: 4203921
[No Abstract] [Full Text] [Related]
[Next] [New Search]
